See You at CCTB 2024 | You Send the Samples, We Cover the Cost — ProteinT Will Be There
Published: 2024-05-07
A new chapter written by the Qinhuai River, a new journey begun in the city of Jinling. From 19 to 21 April 2024, the Chinese Conference on Tumor Biomarkers (CCTB) will be held at the Nanjing International Youth Cultural Centre. This year's conference is hosted by the Tumor Marker Professional Committee of the Chinese Anti-Cancer Association together with Nanjing Medical University.
As a leader in clinical proteomics, ProteinT will make a strong appearance at this gathering, bringing technological breakthroughs and major products including assay kits, and presenting a comprehensive picture of its precision clinical solutions for the diagnosis and treatment of diseases using tumor biomarkers based on proteomics and other multi-omics approaches. Coinciding with the company's tenth anniversary, ProteinT will also release the "Free T Program" to support the application and translation of precision medicine projects — no gimmicks! Fee reductions! Matching support! Experts and scholars are warmly invited to visit the ProteinT booth, 5F-A08, to exchange ideas and discuss breakthroughs and the future of cancer prevention and treatment.
Booth information
Dates: 19–21 April 2024
Venue: Nanjing International Youth Cultural Centre
ProteinT has long been deeply engaged in proteomics and other multi-omics fields. After years of technical accumulation and breakthroughs, its exclusively self-developed platform for discovering novel liquid biopsy biomarkers — n-LAPE/MS™, based on next-generation nano-scale low-abundance protein enrichment mass spectrometry — has reached new heights. Combined with the latest 4D mass spectrometry platform, a single body fluid sample can yield detection of as many as 8,000+ proteins within an effective half-hour gradient, and tens of thousands of clinical body fluid samples have already been analyzed. At the same time, several self-developed products have been approved and brought to market, including a fully automated sample processing system (Tianjin medical device filing No. 20240319) and reagents for plasma protein and peptide extraction or purification (Tianjin medical device filing No. 20230397).
Free T ProgramTo support clinical medical research and to explore the discovery of protein biomarkers for early screening, early diagnosis and disease course monitoring, ProteinT has joined forces with the Tianjin Key Laboratory of Clinical Multi-Omics to launch the "Free T Program." The programme focuses on supporting large-cohort projects whose primary research object is body fluid proteomics. For eligible projects in the relevant fields, it offers a range of support packages worth up to RMB 10 million. Submit your basic details and project information to apply; after review by the expert committee, a dedicated colleague will contact you. We look forward to working with you to advance the application and translation of precision medicine projects.
